Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia Journal Article

   

Authors:	Watts, J. M.; Dumitriu, B.; Hilden, P.; Kishtagari, A.; Rapaport, F.; Chen, C.; Ahn, J.; Devlin, S. M.; Stein, E. M.; Rampal, R.; Levine, R. L.; Young, N.; Tallman, M. S.
Article Title:	Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia
Abstract:	We examined the genetic implications and clinical impact of telomere length (TL) in 67 patients with acute myeloid leukemia (AML). There was a trend toward improved survival at 6 months in patients with longer TL. We found that patients with activating mutations, such as FLT3-ITD, had shorter TL, while those with mutations in epigenetic modifying enzymes, particularly IDH1 and IDH2, had longer TL. These are intriguing findings that warrant further investigation in larger cohorts. Our data show the potential of TL as a predictive biomarker in AML and identify genetic subsets that may be particularly vulnerable to telomere-targeted therapies. © 2016 Elsevier Ltd
Keywords:	acute myeloid leukemia; somatic mutations; telomere length; clinical outcomes
Journal Title:	Leukemia Research
Volume:	49
ISSN:	0145-2126
Publisher:	Elsevier Ltd
Date Published:	2016-10-01
Start Page:	62
End Page:	65
Language:	English
DOI:	10.1016/j.leukres.2016.07.013
PROVIDER:	scopus
PUBMED:	27568819
PMCID:	PMC5526052
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-84983750725&partnerID=40&md5=038875d43f045cd2c4ce1d6379d4147f
Notes:	Article -- Export Date: 3 October 2016 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/98508